CS
OMGA

Credit Suisse’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History

Credit Suisse’s Portfolio OMGA Stock Details OMGA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-12
Closed – – 4361
2022
Q2 		$0 Buy
+12
New +$45 ﹤0.01% 4402

Other funds holding OMGA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Credit Suisse's OMGA Position: Q3 2022 in Review

Credit Suisse sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q3 2022, closing a stake of 12 shares.

Credit Suisse first reported a position in OMGA in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 44 funds tracked by Wall St. Rank hold OMGA as of Q3 2022.

  • Credit Suisse reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 12 Omega Therapeutics, Inc. Common Stock shares in Q3 2022.
  • Credit Suisse first reported a position in Omega Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Credit Suisse's Omega Therapeutics, Inc. Common Stock position peaked at $0 in Q2 2022.
  • 44 funds tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.